{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:11:43Z","timestamp":1793851903236,"version":"4.6.1"},"reference-count":242,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2021,5,4]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations. While glucocorticoids remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. Glucocorticoid-sparing alternatives are available. The presented treatment guidelines aim to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A European Respiratory Society Task Force committee composed of clinicians, methodologists and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight PICO (Patients, Intervention, Comparison, Outcomes) questions and these were used to make specific evidence-based recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Task Force committee delivered 12 recommendations for seven PICOs. These included treatment of pulmonary, cutaneous, cardiac and neurologic disease as well as fatigue. One PICO question regarding small-fibre neuropathy had insufficient evidence to support a recommendation. In addition to the recommendations, the committee provided information on how they use alternative treatments, when there was insufficient evidence to support a recommendation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There are many treatments available to treat sarcoidosis. Given the diverse nature of the disease, treatment decisions require an assessment of organ involvement, risk for significant morbidity, and impact on QoL of the disease and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.04079-2020","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T12:40:37Z","timestamp":1623933637000},"page":"2004079","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":581,"title":["ERS clinical practice guidelines on treatment of sarcoidosis"],"prefix":"10.1183","volume":"58","author":[{"given":"Robert P.","family":"Baughman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valeyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-5680","authenticated-orcid":false,"given":"Peter","family":"Korsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-9616","authenticated-orcid":false,"given":"Alexander G.","family":"Mathioudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-3497","authenticated-orcid":false,"given":"Wim A.","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiliaro","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse E.","family":"Lower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Israel-Biet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-0110","authenticated-orcid":false,"given":"Marjolein","family":"Drent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-9767","authenticated-orcid":false,"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Martone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Quadder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blin","family":"Nagavci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomy","family":"Tonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rigau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Ouellette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"2026061109052013000_58.6.2004079.1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.ats4-99"},{"key":"2026061109052013000_58.6.2004079.2","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0251ST"},{"key":"2026061109052013000_58.6.2004079.4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0146-2019"},{"key":"2026061109052013000_58.6.2004079.5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0145-2019"},{"key":"2026061109052013000_58.6.2004079.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.07.008"},{"key":"2026061109052013000_58.6.2004079.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01815-2017"},{"key":"2026061109052013000_58.6.2004079.8","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1038\/s41598-019-40030-w","article-title":"Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension","volume":"9","author":"Parikh","year":"2019","journal-title":"Sci Rep"},{"key":"2026061109052013000_58.6.2004079.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201010-1679OC"},{"key":"2026061109052013000_58.6.2004079.10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2026061109052013000_58.6.2004079.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01747-2019"},{"key":"2026061109052013000_58.6.2004079.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105997"},{"key":"2026061109052013000_58.6.2004079.13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026061109052013000_58.6.2004079.14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1262216"},{"key":"2026061109052013000_58.6.2004079.15","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e32832d0403"},{"key":"2026061109052013000_58.6.2004079.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.09.014"},{"key":"2026061109052013000_58.6.2004079.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.03.011"},{"key":"2026061109052013000_58.6.2004079.18","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00141-2018"},{"key":"2026061109052013000_58.6.2004079.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00221-2018"},{"key":"2026061109052013000_58.6.2004079.20","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.2.5261.1165","article-title":"Prognosis of intrathoracic sarcoidosis in England","volume":"4","author":"Scadding","year":"1961","journal-title":"Br Med J"},{"key":"2026061109052013000_58.6.2004079.21","first-page":"26","article-title":"Management of ocular sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90011-8"},{"key":"2026061109052013000_58.6.2004079.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1844-0"},{"key":"2026061109052013000_58.6.2004079.24","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.2.1062"},{"key":"2026061109052013000_58.6.2004079.25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamaophthalmol.2017.0603","article-title":"Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials","volume":"135","author":"Sheppard","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2026061109052013000_58.6.2004079.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"2026061109052013000_58.6.2004079.27","first-page":"74","article-title":"Efficacy and safety of TNF antagonists in ocular sarcoidosis: data from the French registry STAT","volume":"34","author":"Marquet","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.28","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.3.623"},{"key":"2026061109052013000_58.6.2004079.29","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.149.4.8143052"},{"key":"2026061109052013000_58.6.2004079.30","first-page":"52","article-title":"The late follow-up of chronic sarcoid patients previously treated with corticosteroids","volume":"15","author":"Rizzato","year":"1998","journal-title":"Sarcoidosis"},{"key":"2026061109052013000_58.6.2004079.31","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcl038"},{"key":"2026061109052013000_58.6.2004079.32","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.8.742"},{"key":"2026061109052013000_58.6.2004079.33","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00055213"},{"key":"2026061109052013000_58.6.2004079.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01518.x"},{"key":"2026061109052013000_58.6.2004079.35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004644"},{"key":"2026061109052013000_58.6.2004079.36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","article-title":"Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: experience from a high volume center","volume":"157","author":"Gangemi","year":"2019","journal-title":"Respir Med"},{"key":"2026061109052013000_58.6.2004079.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2012.07.013"},{"key":"2026061109052013000_58.6.2004079.38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.3.990"},{"key":"2026061109052013000_58.6.2004079.39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060612"},{"key":"2026061109052013000_58.6.2004079.40","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1486706"},{"key":"2026061109052013000_58.6.2004079.41","first-page":"e2020001","article-title":"Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a 6\u2005year period","volume":"37","author":"Baughman","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.42","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.43","first-page":"834","article-title":"Use of third-line therapies in advanced sarcoidosis","volume":"38","author":"Lower","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2026061109052013000_58.6.2004079.44","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.45","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1728"},{"key":"2026061109052013000_58.6.2004079.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.09.013"},{"key":"2026061109052013000_58.6.2004079.47","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.48","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-017-9994-4"},{"key":"2026061109052013000_58.6.2004079.49","first-page":"46","article-title":"A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society study of long-term corticosteroid treatment","volume":"14","author":"Muers","year":"1997","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.50","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2822"},{"key":"2026061109052013000_58.6.2004079.51","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.6.1321"},{"key":"2026061109052013000_58.6.2004079.52","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2026061109052013000_58.6.2004079.53","doi-asserted-by":"publisher","DOI":"10.1348\/1359107041557048"},{"key":"2026061109052013000_58.6.2004079.54","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1785OC"},{"key":"2026061109052013000_58.6.2004079.55","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201962"},{"key":"2026061109052013000_58.6.2004079.56","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809030-00003"},{"key":"2026061109052013000_58.6.2004079.57","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamadermatol.2013.60","article-title":"Reliability and convergent validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument for assessing cutaneous sarcoidosis","volume":"149","author":"Rosenbach","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026061109052013000_58.6.2004079.58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2026061109052013000_58.6.2004079.59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2026061109052013000_58.6.2004079.60","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"2026061109052013000_58.6.2004079.61","unstructured":"Higgins JP , Thomas J . Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1. London, Cochrane, 2021."},{"key":"2026061109052013000_58.6.2004079.62","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026061109052013000_58.6.2004079.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.02.003"},{"key":"2026061109052013000_58.6.2004079.64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2016"},{"key":"2026061109052013000_58.6.2004079.65","doi-asserted-by":"publisher","DOI":"10.36141\/SVDLD.V34I4.6957"},{"key":"2026061109052013000_58.6.2004079.66","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02396-2016"},{"key":"2026061109052013000_58.6.2004079.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.12.033"},{"key":"2026061109052013000_58.6.2004079.68","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00897-2019"},{"key":"2026061109052013000_58.6.2004079.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.08.012"},{"key":"2026061109052013000_58.6.2004079.70","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.104380"},{"key":"2026061109052013000_58.6.2004079.71","first-page":"372","article-title":"Role of serial F-18 FDG PET\/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis","volume":"33","author":"Maturu","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.72","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00227014"},{"key":"2026061109052013000_58.6.2004079.73","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","article-title":"Efficacy and safety of infliximab biosimilar Inflectra in severe sarcoidosis","volume":"138S","author":"Schimmelpennink","year":"2018","journal-title":"Respir Med"},{"key":"2026061109052013000_58.6.2004079.74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00430-2019"},{"key":"2026061109052013000_58.6.2004079.75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(67)90493-X"},{"key":"2026061109052013000_58.6.2004079.76","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1973.107.4.609"},{"key":"2026061109052013000_58.6.2004079.77","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.2.424"},{"key":"2026061109052013000_58.6.2004079.78","first-page":"496","article-title":"Corticosteroid therapy in sarcoidosis: a 5\u2005year controlled follow-up","volume":"87","author":"Zaki","year":"1987","journal-title":"NY State J Med"},{"key":"2026061109052013000_58.6.2004079.79","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.1.24"},{"key":"2026061109052013000_58.6.2004079.80","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.3.238"},{"key":"2026061109052013000_58.6.2004079.81","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181b97635"},{"key":"2026061109052013000_58.6.2004079.82","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.rmed.2017.10.022","article-title":"No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis","volume":"138S","author":"Broos","year":"2018","journal-title":"Respir Med"},{"key":"2026061109052013000_58.6.2004079.83","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-73-2-207"},{"key":"2026061109052013000_58.6.2004079.84","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.13613519"},{"key":"2026061109052013000_58.6.2004079.85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00798.x"},{"key":"2026061109052013000_58.6.2004079.86","first-page":"198","article-title":"Use of fluticasone in acute symptomatic pulmonary sarcoidosis","volume":"19","author":"Baughman","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.87","first-page":"CD001114","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"2","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2026061109052013000_58.6.2004079.88","first-page":"275","article-title":"Features of sarcoidosis associated with chronic disease","volume":"31","author":"Baughman","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.89","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.46.538.537"},{"key":"2026061109052013000_58.6.2004079.90","first-page":"215","article-title":"Corticosteroid therapy of pulmonary sarcoidosis","volume":"60","author":"Selroos","year":"1979","journal-title":"Scand J Respir Dis"},{"key":"2026061109052013000_58.6.2004079.91","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(66)90216-6"},{"key":"2026061109052013000_58.6.2004079.92","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09030406"},{"key":"2026061109052013000_58.6.2004079.93","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.94","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"key":"2026061109052013000_58.6.2004079.95","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"key":"2026061109052013000_58.6.2004079.96","first-page":"201","article-title":"A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.97","first-page":"121","article-title":"Steroid sparing effects of pentoxifylline in pulmonary sarcoidosis","volume":"26","author":"Park","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.98","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1164\/ajrccm.156.5.9506031","article-title":"Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial","volume":"156","author":"Wyser","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061109052013000_58.6.2004079.99","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430080088011"},{"key":"2026061109052013000_58.6.2004079.100","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study","volume":"36","author":"Fang","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.101","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.14511179"},{"key":"2026061109052013000_58.6.2004079.102","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00195010"},{"key":"2026061109052013000_58.6.2004079.103","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.1.9809024"},{"key":"2026061109052013000_58.6.2004079.104","doi-asserted-by":"crossref","first-page":"302S","DOI":"10.1111\/j.0954-6820.1964.tb05780.x","article-title":"Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis","volume":"425","author":"Siltzbach","year":"1964","journal-title":"Acta Med Scand"},{"key":"2026061109052013000_58.6.2004079.105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s11845-015-1363-9","article-title":"Adalimumab for refractory pulmonary sarcoidosis","volume":"185","author":"Minnis","year":"2016","journal-title":"Ir J Med Sci"},{"key":"2026061109052013000_58.6.2004079.106","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00224513"},{"key":"2026061109052013000_58.6.2004079.107","first-page":"201","article-title":"Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis","volume":"30","author":"Drake","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.108","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis","volume":"159","author":"Drake","year":"2021","journal-title":"Chest"},{"key":"2026061109052013000_58.6.2004079.109","doi-asserted-by":"crossref","first-page":"1753466619888127","DOI":"10.1177\/1753466619888127","article-title":"Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records","volume":"13","author":"Chopra","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"2026061109052013000_58.6.2004079.110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2015.11.007","article-title":"A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients","volume":"110","author":"Baughman","year":"2016","journal-title":"Respir Med"},{"key":"2026061109052013000_58.6.2004079.111","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chest.2017.09.042","article-title":"Higher priced older pharmaceuticals: how should we respond?","volume":"153","author":"Irwin","year":"2018","journal-title":"Chest"},{"key":"2026061109052013000_58.6.2004079.112","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01482-2018"},{"key":"2026061109052013000_58.6.2004079.113","first-page":"100004","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","volume":"1","author":"Sharp","year":"2019","journal-title":"Respir Med X"},{"key":"2026061109052013000_58.6.2004079.114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026061109052013000_58.6.2004079.115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361706"},{"key":"2026061109052013000_58.6.2004079.116","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.74.877.649"},{"key":"2026061109052013000_58.6.2004079.117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2015.08.010"},{"key":"2026061109052013000_58.6.2004079.118","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06815.x"},{"key":"2026061109052013000_58.6.2004079.119","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1985.tb04859.x"},{"key":"2026061109052013000_58.6.2004079.120","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1347"},{"key":"2026061109052013000_58.6.2004079.121","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.03.011"},{"key":"2026061109052013000_58.6.2004079.122","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.2085"},{"key":"2026061109052013000_58.6.2004079.123","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamadermatol.2013.4646","article-title":"Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study","volume":"149","author":"Drake","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026061109052013000_58.6.2004079.124","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.125","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01729.x"},{"key":"2026061109052013000_58.6.2004079.126","first-page":"153","article-title":"Cutaneous sarcoidosis: a case series from a regional hospital in Hong Kong","volume":"20","author":"Chang","year":"2012","journal-title":"Hong Kong J Dermatol Venereol"},{"key":"2026061109052013000_58.6.2004079.127","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.13760","article-title":"Epidemiology of cutaneous sarcoidosis, 1976\u20132013: a population-based study from Olmsted County, Minnesota","volume":"30","author":"Ungprasert","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026061109052013000_58.6.2004079.128","first-page":"372","article-title":"Comparison of cutaneous sarcoidosis with systemic sarcoidosis: a retrospective analysis","volume":"7","author":"Tong","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"2026061109052013000_58.6.2004079.129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2230.2009.03400.x","article-title":"A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department","volume":"35","author":"Collin","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"2026061109052013000_58.6.2004079.130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.001"},{"key":"2026061109052013000_58.6.2004079.131","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2340\/00015555726971","article-title":"Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing","volume":"72","author":"Volden","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"2026061109052013000_58.6.2004079.132","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.131.5.617"},{"key":"2026061109052013000_58.6.2004079.133","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(81)70017-3"},{"key":"2026061109052013000_58.6.2004079.134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.019"},{"key":"2026061109052013000_58.6.2004079.135","first-page":"136","article-title":"High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis","volume":"34","author":"Noe","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.136","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.137","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1378\/chest.14-0015","article-title":"A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis","volume":"146","author":"Droitcourt","year":"2014","journal-title":"Chest"},{"key":"2026061109052013000_58.6.2004079.138","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00051907"},{"key":"2026061109052013000_58.6.2004079.139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.056"},{"key":"2026061109052013000_58.6.2004079.140","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.227"},{"key":"2026061109052013000_58.6.2004079.141","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-3879(67)80033-3"},{"key":"2026061109052013000_58.6.2004079.142","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0190-9622(90)70246-E","article-title":"Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas","volume":"23","author":"Jones","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2026061109052013000_58.6.2004079.143","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70071-9"},{"key":"2026061109052013000_58.6.2004079.144","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70306-8"},{"key":"2026061109052013000_58.6.2004079.145","first-page":"S335","article-title":"Methotrexate in the treatment of cutaneous sarcoidosis","volume":"11","author":"Rajendran","year":"1994","journal-title":"Sarcoidosis"},{"key":"2026061109052013000_58.6.2004079.146","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.10.2104046"},{"key":"2026061109052013000_58.6.2004079.147","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.851352"},{"key":"2026061109052013000_58.6.2004079.148","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.58.6.1204"},{"key":"2026061109052013000_58.6.2004079.149","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1513\/AnnalsATS.201902-119CME","article-title":"Update in cardiac sarcoidosis","volume":"16","author":"Ribeiro Neto","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2026061109052013000_58.6.2004079.150","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-305187"},{"key":"2026061109052013000_58.6.2004079.151","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005001"},{"key":"2026061109052013000_58.6.2004079.152","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.022"},{"key":"2026061109052013000_58.6.2004079.153","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01978-6"},{"key":"2026061109052013000_58.6.2004079.154","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ejhf.1319","article-title":"Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres","volume":"20","author":"Fussner","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026061109052013000_58.6.2004079.155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chest.2016.08.1457","article-title":"Cardiac sarcoidosis: the impact of age and implanted devices on survival","volume":"151","author":"Zhou","year":"2017","journal-title":"Chest"},{"key":"2026061109052013000_58.6.2004079.156","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-018-01504-y"},{"key":"2026061109052013000_58.6.2004079.157","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.06.021"},{"key":"2026061109052013000_58.6.2004079.158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2017.04.020"},{"key":"2026061109052013000_58.6.2004079.159","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.205"},{"key":"2026061109052013000_58.6.2004079.160","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.10.035"},{"key":"2026061109052013000_58.6.2004079.161","doi-asserted-by":"crossref","first-page":"e007488","DOI":"10.1161\/CIRCEP.119.007488","article-title":"Assessment of the 2017 AHA\/ACC\/HRS guideline recommendations for implantable cardioverter-defibrillator implantation in cardiac sarcoidosis","volume":"12","author":"Kazmirczak","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026061109052013000_58.6.2004079.162","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2014.03.043"},{"key":"2026061109052013000_58.6.2004079.163","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12350-017-1043-4","article-title":"A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology","volume":"25","author":"Slart","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"2026061109052013000_58.6.2004079.164","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.0794"},{"key":"2026061109052013000_58.6.2004079.165","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijcard.2016.10.101","article-title":"Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis","volume":"227","author":"Padala","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026061109052013000_58.6.2004079.166","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-1275"},{"key":"2026061109052013000_58.6.2004079.167","first-page":"133","article-title":"Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block","volume":"20","author":"Kato","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.168","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.003738"},{"key":"2026061109052013000_58.6.2004079.169","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.acvd.2016.12.014","article-title":"Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors","volume":"110","author":"Chapelon-Abric","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"2026061109052013000_58.6.2004079.170","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000145367.17934.75"},{"key":"2026061109052013000_58.6.2004079.171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2012.10.021"},{"key":"2026061109052013000_58.6.2004079.172","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/jce.12302","article-title":"Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator","volume":"25","author":"Mohsen","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026061109052013000_58.6.2004079.173","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-010-0376-8"},{"key":"2026061109052013000_58.6.2004079.174","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.011522"},{"key":"2026061109052013000_58.6.2004079.175","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-1217"},{"key":"2026061109052013000_58.6.2004079.176","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijcard.2014.07.042","article-title":"Reduction of myocardial inflammation with steroid is not necessarily associated with improvement in left ventricular function in patients with cardiac sarcoidosis: predictors of functional improvement","volume":"176","author":"Takaya","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026061109052013000_58.6.2004079.177","first-page":"16","article-title":"A case with cardiac sarcoidosis. Significance of the effect of steroids on the reversion of advanced atrioventricular block and myocardial scintigraphic abnormalities","volume":"5","author":"Fujita","year":"1990","journal-title":"Heart Vessels Suppl"},{"key":"2026061109052013000_58.6.2004079.178","first-page":"210","article-title":"National survey on status of steroid therapy for cardiac sarcoidosis in Japan","volume":"22","author":"Hiramitsu","year":"2005","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.179","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ehf2.12095","article-title":"Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction","volume":"3","author":"Okabe","year":"2016","journal-title":"ESC Heart Fail"},{"key":"2026061109052013000_58.6.2004079.180","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0139"},{"key":"2026061109052013000_58.6.2004079.181","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.09.003"},{"key":"2026061109052013000_58.6.2004079.182","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.11.131"},{"key":"2026061109052013000_58.6.2004079.183","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.07.067"},{"key":"2026061109052013000_58.6.2004079.184","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.semarthrit.2019.11.004","article-title":"TNF-alpha inhibition for the treatment of cardiac sarcoidosis","volume":"50","author":"Baker","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2026061109052013000_58.6.2004079.185","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2013.02.004"},{"key":"2026061109052013000_58.6.2004079.186","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0263"},{"key":"2026061109052013000_58.6.2004079.187","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X15666190725121246"},{"key":"2026061109052013000_58.6.2004079.188","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.189","first-page":"228","article-title":"A prospective study of patients diagnosed with sarcoidosis: factors \u2013 environmental exposure, health assessment, and genetic outlooks","volume":"36","author":"Caruana","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.190","first-page":"154","article-title":"Predicting respiratory failure in sarcoidosis patients","volume":"14","author":"Baughman","year":"1997","journal-title":"Sarcoidosis"},{"key":"2026061109052013000_58.6.2004079.191","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol"},{"key":"2026061109052013000_58.6.2004079.192","doi-asserted-by":"crossref","first-page":"117073","DOI":"10.1016\/j.jns.2020.117073","article-title":"The effect of race on clinical presentation and outcomes in neurosarcoidosis","volume":"417","author":"Affan","year":"2020","journal-title":"J Neurol Sci"},{"key":"2026061109052013000_58.6.2004079.193","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group","volume":"75","author":"Stern","year":"2018","journal-title":"JAMA Neurol"},{"key":"2026061109052013000_58.6.2004079.194","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0741-x"},{"key":"2026061109052013000_58.6.2004079.195","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003431"},{"key":"2026061109052013000_58.6.2004079.196","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440370104011"},{"key":"2026061109052013000_58.6.2004079.197","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1756-185X.12122","article-title":"Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab","volume":"17","author":"Metyas","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"2026061109052013000_58.6.2004079.198","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00415-009-0077-1","article-title":"Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab","volume":"256","author":"Marnane","year":"2009","journal-title":"J Neurol"},{"key":"2026061109052013000_58.6.2004079.199","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.5.2023"},{"key":"2026061109052013000_58.6.2004079.200","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8444-9"},{"key":"2026061109052013000_58.6.2004079.201","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00408-019-00206-7","article-title":"The burden of sarcoidosis symptoms from a patient perspective","volume":"197","author":"Voortman","year":"2019","journal-title":"Lung"},{"key":"2026061109052013000_58.6.2004079.202","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.4.989"},{"key":"2026061109052013000_58.6.2004079.203","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-2629"},{"key":"2026061109052013000_58.6.2004079.204","first-page":"2","article-title":"Patient reported outcome measures (PROM) in sarcoidosis","volume":"34","author":"Thunold","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.205","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2952"},{"key":"2026061109052013000_58.6.2004079.206","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.02.016"},{"key":"2026061109052013000_58.6.2004079.207","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HCR.0000000000000307","article-title":"Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial","volume":"38","author":"Naz","year":"2018","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026061109052013000_58.6.2004079.208","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04312"},{"key":"2026061109052013000_58.6.2004079.209","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2012.00332"},{"key":"2026061109052013000_58.6.2004079.210","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.03.011"},{"key":"2026061109052013000_58.6.2004079.211","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-0996-4"},{"key":"2026061109052013000_58.6.2004079.212","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17476348.2016.1227244","article-title":"Physical activity and training in sarcoidosis: review and experience-based recommendations","volume":"10","author":"Strookappe","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"2026061109052013000_58.6.2004079.213","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000486964","article-title":"Short-term effects of a multimodal 3-week inpatient pulmonary rehabilitation programme for patients with sarcoidosis: the ProKaSaRe study","volume":"95","author":"Lingner","year":"2018","journal-title":"Respiration"},{"key":"2026061109052013000_58.6.2004079.214","first-page":"53","article-title":"Does physical training reduce fatigue in sarcoidosis?","volume":"32","author":"Marcellis","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00408-015-9784-9","article-title":"Benefits of physical training in sarcoidosis","volume":"193","author":"Strookappe","year":"2015","journal-title":"Lung"},{"key":"2026061109052013000_58.6.2004079.216","first-page":"1","article-title":"Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: a randomized controlled trial","volume":"77","author":"Wallaert","year":"2020","journal-title":"Respir Med Res"},{"key":"2026061109052013000_58.6.2004079.217","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0057-2019"},{"key":"2026061109052013000_58.6.2004079.218","doi-asserted-by":"crossref","first-page":"105936","DOI":"10.1016\/j.rmed.2020.105936","article-title":"Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis","volume":"165","author":"Vis","year":"2020","journal-title":"Respir Med"},{"key":"2026061109052013000_58.6.2004079.219","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/MCP.0000000000000413","article-title":"Small fiber neuropathy: a disabling and underrecognized syndrome","volume":"23","author":"Voortman","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"2026061109052013000_58.6.2004079.220","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bacf05"},{"key":"2026061109052013000_58.6.2004079.221","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23107-w"},{"key":"2026061109052013000_58.6.2004079.222","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-011-0180-8"},{"key":"2026061109052013000_58.6.2004079.223","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08912-2"},{"key":"2026061109052013000_58.6.2004079.224","first-page":"333","article-title":"Determinaton of the smallest detectable change and minimal important change (MIC) for the small fiber neuropathy screening list (SFNSL) in sarcoidosis","volume":"35","author":"Voortman","year":"2018","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.225","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.76a.08070"},{"key":"2026061109052013000_58.6.2004079.226","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2119\/molmed.2013.00122","article-title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","volume":"19","author":"Dahan","year":"2013","journal-title":"Mol Med"},{"key":"2026061109052013000_58.6.2004079.227","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-21291"},{"key":"2026061109052013000_58.6.2004079.228","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.09.015"},{"key":"2026061109052013000_58.6.2004079.229","first-page":"73","article-title":"Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab","volume":"23","author":"Hoitsma","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.230","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jneuroim.2010.09.015","article-title":"Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies","volume":"231","author":"Lehmann","year":"2011","journal-title":"J Neuroimmunol"},{"key":"2026061109052013000_58.6.2004079.231","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11481-012-9428-2","article-title":"Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain","volume":"8","author":"Sacerdote","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"2026061109052013000_58.6.2004079.232","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00169413"},{"key":"2026061109052013000_58.6.2004079.233","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03239-0"},{"key":"2026061109052013000_58.6.2004079.234","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2119\/molmed.2014.00215","article-title":"ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes","volume":"20","author":"Brines","year":"2015","journal-title":"Mol Med"},{"key":"2026061109052013000_58.6.2004079.235","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1687"},{"key":"2026061109052013000_58.6.2004079.236","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60680-7"},{"key":"2026061109052013000_58.6.2004079.237","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.238","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200807-1082OC"},{"key":"2026061109052013000_58.6.2004079.239","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCP.0000000000000604","article-title":"Indications for treatment of sarcoidosis","volume":"25","author":"Nunes","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2026061109052013000_58.6.2004079.240","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir Med"},{"key":"2026061109052013000_58.6.2004079.241","first-page":"254","article-title":"Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome","volume":"36","author":"Lower","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026061109052013000_58.6.2004079.242","first-page":"86","article-title":"A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS)","volume":"36","author":"Baughman","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.04079-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:05:39Z","timestamp":1781193939000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.04079-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":242,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12,16]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1183\/13993003.04079-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.04079-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}